Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 2. CYM50358 represses OVA-induced immune cell accumulation in BALF. (A) Mice were sensitized with OVA twice by i.p. injection on day 0 (D0) and D14, and later challenged on D28, D29, and D30 with nebulized OVA. CYM50358 was administrated intraperitoneally at the dose of 10 mg/kg, 30 min before OVA sensitization or before OVA challenge. BALF cells were stained using May-Grünwald stain and counted. (B) Total cell counts, eosinophils, and macrophages in BALF. (C) Lymphocytes counts in the BALF. The results are presented as the mean ± SE cell count values (n=5). ***p<0.001 vs. the PBS-treated group, ##p<0.01, ###p<0.001 vs. the OVA-treated group.
Biomolecules & Therapeutics 2021;29:492~497 https://doi.org/10.4062/biomolther.2020.206
© Biomolecules & Therapeutics